

Technical Note

## Optimization of CE-ICP-MS/MS method for investigation of the liposome–cisplatin nanosystems and their interactions with transferrin

Anna M. Wróblewska,<sup>a</sup> Jan Samsonowicz–Górski,<sup>a</sup> Ewelina Kamińska,<sup>a</sup> Marcin Drozd<sup>bc</sup> and Magdalena Matczuk<sup>\* a</sup>

<sup>a</sup> Chair of Analytical Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego St. 3, 00-664 Warsaw, Poland. E-mail: mmaczuk@ch.pw.edu.pl, Tel.: +48 222347719


<sup>b</sup> Chair of Medical Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego St. 3, 00-664 Warsaw, Poland.

<sup>c</sup> Centre for Advanced Materials and Technologies CEZAMAT, Warsaw University of Technology, Poleczki Str. 19, 02-822 Warsaw, Poland.


**Table S1.** Compositions of formed liposomes: the molar ratios and weighted amounts of reagents

Formulation		Lipids							Lit.	
		DSPE-PEG (2000)	DSPC	HSPC	Chol	DOPC*	DSPG-Na	POPC		DPPC
S1	Molar ratio	–	–	60	40	–	–	–	–	1
	Weight [g]	–	–	0.0047	0.0012	–	–	–	–	–
S2	Molar ratio	–	–	–	30	–	25	–	45	2
	Weight [g]	–	–	–	0.0013	–	0.0028	–	0.0050	–
E1	Molar ratio	5	70	–	–	–	25	–	–	3
	Weight [g]	0.0014	0.0055	–	–	–	0.0019	–	–	–
E4	Molar ratio	5.3	–	56.3	38.4	–	–	–	–	2
	Weight [g]	0.0015	–	0.0044	0.0011	–	–	–	–	–
E6	Molar ratio	10	–	–	36	54	–	–	–	4
	Weight [g]	0.0028	–	–	0.0010	0.0041	–	–	–	–
E4_mod1	Molar ratio	5.3	56.3	–	38.4	–	–	–	–	–
	Weight [g]	0.0015	0.0045	–	0.0011	–	–	–	–	–
E4_mod2	Molar ratio	3	–	31.3	65.7	–	–	–	–	–
	Weight [g]	0.0015	–	0.0044	0.0033	–	–	–	–	–
E6_mod1	Molar ratio	10	–	–	36	–	–	54	–	–
	Weight [g]	0.0028	–	–	0.0010	–	–	0.0041	–	–


\* DOPC was used as a substitute of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)




**Fig. S1.** DLS analysis of E6 liposomes' sample diluted 200 times in incubation solution. Inset shows calculated mean values ( $n = 3$ ) of hydrodynamic diameter ( $d$ ) and polydispersity index (PDI)




**Fig. S2.** DLS analysis of E4 liposomes' sample diluted 200 times in incubation solution. Inset shows calculated mean values ( $n = 3$ ) of hydrodynamic diameter ( $d$ ) and polydispersity index (PDI)



**Fig. S3.** Product ion of  $m/z$  equal 31 ( $^{31}\text{P}^+ \rightarrow ^{31}\text{P}^{16}\text{O}^+$ ), oxygen used as reaction/collision gas



**Fig. S4.** Precursor ion of  $m/z$  equal 47 ( $^{31}\text{P}^{16}\text{O}^+$ ), oxygen used as reaction/collision gas




**Fig. S5.** Product ion of  $m/z$  equal 195 ( $^{195}\text{Pt}^+ \rightarrow ^{195}\text{Pt}^+$ ), oxygen used as reaction/collision gas

The resolution ( $R$ ) was calculated based on the cisplatin and liposome peaks MTs ( $t_1$  and  $t_2$ , respectively) and width at the base ( $W_1$  and  $W_2$ , respectively) according to the following Equation (1).

$$R = \frac{2(t_2 - t_1)}{W_1 + W_2} \quad (1)$$

The symmetry ( $S$ ) of phosphorus peaks was calculated as the quotient of the differences between the time of the peak's end ( $t_{II}$ ) and MT ( $t$ ), and the difference between MT and time of the peak's beginning ( $t_I$ ) (see the Equation (2) below).

$$S = \frac{t_{II} - t}{t - t_I} \quad (2)$$



**Fig. S6.** CE-ICP-MS/MS electropherograms of liposomes samples analysed under various BGE concentration conditions; voltage +15 kV (current  $\sim 3 \mu\text{A}$ ), injection: 50 mbar  $\times$  7 s, capillary: fused silica, length 70 cm (i.d. 75  $\mu\text{m}$ )

To calculate the limit of detection (LOD) of particular analytes (substrates: cisplatin and not encapsulated liposomes), the ratio of noise ( $N$ ) to signal ( $S$ ) intensities was defined and multiplied by 3, and by the concentration ( $C$ ) of the analyte in the sample (Equation (3)).


$$LOD = 3 \cdot \frac{N}{S} \cdot C \quad [M] \quad (3)$$

The limit of quantification (LOQ) of particular analytes was calculated as corresponding LOD's triplicate (Equation (4)).


$$LOQ = 3 \cdot LOD \quad [M] \quad (4)$$

The recovery value was calculated by dividing the average of peaks' areas ( $n=3$ ) corresponding to a  $^{31}\text{P}^{16}\text{O}^+$  (not encapsulated liposomes) obtained during the analysis run under optimized conditions ( $PA_{optimal}$ ) by the average of peaks' areas ( $n=3$ ) obtained during the analysis conducted with applied 20 mbar of internal pressure ( $PA_{20mbar}$ ).


$$Recovery = \frac{PA_{optimal}}{PA_{20mbar}} \cdot 100\% \quad [\%] \quad (5)$$



**Fig. S7.** A phospholipids calibration curve (based on E4 liposomes): the linear range of the optimized CE-ICP-MS/MS method for  $^{31}\text{P}^{16}\text{O}^+$  signals quantification



**Fig. S8.** Transferrin calibration curve: the linear range of the optimized CE-ICP-MS/MS method for  $^{32}\text{S}^{16}\text{O}^+$  signals quantification



**Fig. S9.** Cisplatin calibration curve: the linear range of the optimized CE-ICP-MS/MS method for  $^{195}\text{Pt}^+$  signals quantification

## References

- 1 K. Sakai-Kato, K. Yoshida and K. ichi Izutsu, *Chem. Phys. Lipids*, 2019, **224**, 104726.
- 2 F. Weber, L. Rahnfeld and P. Luciani, *Talanta*, 2020, **220**, 121320.
- 3 U. Franzen, T. T. T. N. Nguyen, C. Vermehren, B. Gammelgaard and J. Østergaard, *J. Pharm. Biomed. Anal.*, 2011, **55**, 16–22.
- 4 D. Guimarães, J. Noro, A. Loureiro, A. Cavaco-Paulo and E. Nogueira, *Colloids Surfaces B Biointerfaces*, 2019, **179**, 414–420.